Johnson & Johnson and BeiGene, Ltd.: A Comprehensive Revenue Analysis

Pharma Giants: A Decade of Revenue Growth

__timestamp	BeiGene, Ltd.	Johnson & Johnson
Wednesday, January 1, 2014	13035000	74331000000
Thursday, January 1, 2015	8816000	70074000000
Friday, January 1, 2016	1070000	71890000000
Sunday, January 1, 2017	238387000	76450000000
Monday, January 1, 2018	198220000	81581000000
Tuesday, January 1, 2019	428212000	82059000000
Wednesday, January 1, 2020	308874000	82584000000
Friday, January 1, 2021	1176283000	78740000000
Saturday, January 1, 2022	1415921000	79990000000
Sunday, January 1, 2023	2458779000	85159000000
Monday, January 1, 2024		61350000000

Cracking the code

A Tale of Two Giants: Johnson & Johnson vs. BeiGene, Ltd.

In the ever-evolving landscape of the pharmaceutical industry, Johnson & Johnson and BeiGene, Ltd. stand as two contrasting titans. Over the past decade, Johnson & Johnson has consistently demonstrated its dominance, with revenues peaking at approximately $85 billion in 2023, marking a steady growth of around 15% since 2014. In contrast, BeiGene, Ltd., a rising star in the biotech sector, has shown an impressive revenue surge, skyrocketing from a modest $13 million in 2014 to nearly $2.5 billion in 2023, reflecting a staggering growth rate of over 18,000%.

This analysis highlights the dynamic nature of the pharmaceutical market, where established giants and innovative newcomers coexist. As BeiGene continues to expand its footprint, the competition intensifies, promising exciting developments in the years to come.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025